Tavapadon Is Not Associated With Increased Daytime Sleepiness in People With Parkinson’s Disease
Objective: To evaluate daytime sleepiness in people with Parkinson’s disease (PD) treated with tavapadon as monotherapy (TEMPO-1; NCT04201093) or adjunctive to levodopa (TEMPO-3; NCT04542499). Background:…Who is lost? Monitoring recruitment in the EJS ACT-PD trial to improve understanding of inclusive recruitment
Objective: To improve equitable access to participation in the EJS ACT-PD trial (Edmond J Safra Accelerating Clinical Trials in Parkinson’s Disease) Background: A minority of…Comparative Study of limits of stability Improvements in Young-Onset vs. Late-Onset Parkinson’s Disease Following One-Year Biofeedback Balance Training
Objective: This study aims to assess the impact of balance training and early detection of stability limits in PD on the responsiveness of young and…LRRK2 antisense oligonucleotide (BIIB094/ION859) impact on cerebrospinal fluid biomarkers in Parkinson’s disease patients
Objective: To provide novel fluid biomarker results from REASON – a Phase 1 clinical trial testing a LRRK2 antisense oligonucleotide in both LRRK2-Parkinson’s disease and…Dual-task gait digital assessment unmask the association between dopaminergic deficits and gait parameters in early and prodromal Parkinson’s Disease
Objective: to explore the relationship between dopaminergic deficits and digital gait parameters alterations in de novo PD and iRBD Background: gait alterations are common features…The Impact of Statin Therapy on Motor and Non-Motor Symptoms in Parkinson’s Disease: A Meta-Analysis
Objective: To assess the effects of statin therapy on motor and non-motor symptoms in Parkinson’s disease (PD) through a meta-analysis of randomized controlled trials. Background:…Positive Relationship Between Improvement in Sleep and Quality of Life During Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion
Objective: To investigate the relationship between improvements in sleep disturbances and quality of life (QoL) in adults with advanced Parkinson’s disease (aPD) treated with a…Unraveling the Variability in Amantadine Response for Levodopa-Induced Dyskinesias: The Impact of Clinical and Genetic Factors
Objective: To identify demographic, clinical, and genetic factors associated with the outcomes of amantadine treatment in dyskinetic Parkinson’s disease (PD) patients. Background: While recent advancements…Treatment Stability Across Different ADD-ON Therapies in Fluctuating Parkinson’s Disease
Objective: This study investigates the efficacy and tolerability of selegiline (SL), rasagiline (RS), safinamide (SF), and opicapone (OP) in fluctuating PD patients, focusing on treatment…Phosphorylated High Mobility Group Box Protein 2 (HMGB2) as a Potential Biomarker for Parkinson’s Disease
Objective: We recently showed that HMGB2 is secreted during ferroptosis and as ferroptosis is involved in the etiology of PD, we have examined the possibility…
- « Previous Page
- 1
- …
- 80
- 81
- 82
- 83
- 84
- …
- 436
- Next Page »